Biogen finally scores win in its fight to prevent copycats of MS drug in the EU
After failing to block generics for Tecfidera in the US, Biogen snagged a win in Europe in its fight to prevent copycat versions of its blockbuster multiple sclerosis drug.
According to SEC filings, the European Commission (EC) on Wednesday let Biogen know that it decided to extend regulatory market protection of Tecfidera (dimethyl fumarate) until Feb. 2, 2025. Biogen will have exclusive rights in Europe without the threat of other companies developing generics with the same active ingredients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.